Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury

• References

• 1 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 01: 27-31.
• 2 Celletti FL, Waugh JM, Amabile PG. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 07: 425-9.
• 3 Weis M, Heeschen C, Glassford AJ. et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
• 4 Alber HF, Dulak J, Frick M. et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 2002; 39: 1951-5.
• 5 Blann AD, Belgore FM, Constans J. et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001; 87: 1160-3.
• 6 Kranz A, Rau C, Kochs M. et al. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction: evidence for its origin and functional significance. J Moll Cell Cardiol 2000; 32: 65-72.
• 7 Mohle R, Green D, Moore MA. et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakariocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8.
• 8 Weltermann A, Wolzt M, Petersmann K. et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo . Arterioscler Thromb Vasc Biol 1999; 19: 1757-60.
• 9 Heldin CH, Westermark B. Mechanism of action and in vivo role platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
• 10 Undas A, Celinska-Lowenhoff M, Domagala TB. et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005; 94: 193-9.
• 11 Undas A, Brummel KE, Musial J. et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-53.
• 12 Undas A, Celinska-Löwenhoff M, Kaczor M. et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004; 91: 1065-77.
• 13 Gajdos M, Mongiellova V, Huttova D. et al. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. J Cardiovasc Pharmacol 2001; 38: 651-6.
• 14 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
• 15 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32: 901-8.
• 16 Casani L, Sanchez-Gomez S, Vilahur G. et al. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 2005; 94: 1035-41.
• 17 Heeschen C, Dimmeler S, Hamm CW. et al. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524-30.